The Seawolves' junior forward Malik Jackson was recently diagnosed with acute lymphoblastic leukemia, and his family has set ...

Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Ascentage Pharma’s olverembatinib gets China NMPA’s BTD to treat Philadelphia chromosome-positive acute lymphoblastic leukemia: Rockville Friday, March 7, 2025, 11:00 Hrs [IST ...

For Black Americans, the battle with Chronic Myeloid Leukemia is marked by unique survival challenges and treatment ...

Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma’s key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the ...

Changes in Blood Cell Production Over the Lifetime Could Impact Leukemia Outcomes Dec. 5, 2024 — The first comprehensive map of the dramatic changes that take place in the blood system over the ...

A fundraising campaign has been set up to help the family of a four-year-old Summerland girl who has been diagnosed with ...

Myeloid leukemias are among the most aggressive blood cancers and have low survival rates. Today, leukemia patients undergo ...

In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...

Paolo Ghia, MD, PhD, discusses the CAPTIVATE trial in chronic lymphocytic leukemia/small lymphocytic lymphoma, and what findings from the trial have been particularly noteworthy.